CLINICAL STUDIES
Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina
Terumitsu Tanaka, MD*,
Masatoshi Fujita, MD, FACC ,
Izuru Nakae, MD*,
Shun-Ichi Tamaki, MD*,
Koji Hasegawa, MD ,
Yasuki Kihara, MD,
Ryuji Nohara, MD and
Shigetake Sasayama, MD, FACC
* Division of Cardiology, Takeda Hospital, Kyoto University, Graduate School of Medicine, Kyoto, Japan
College of Medical Technology, Kyoto University, Kyoto, Japan
Department of Cardiovascular Medicine, Kyoto University, Graduate School of Medicine, Kyoto, Japan
Manuscript received March 31, 1998;
revised manuscript received July 16, 1998,
accepted August 6, 1998.
Address for correspondence: Dr. Masatoshi Fujita, College of Medical Technology, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
mfujita{at}kuhp.kyoto-u.ac.jp
Objectives. The purpose of this study was to evaluate whether a serotonin blocker, sarpogrelate, improves exercise capacity as a result of vasodilation of coronary collateral channels in patients with effort angina.
Background. Serotonin has been reported to decrease coronary collateral blood flow by collateral vasoconstriction in a canine model, suggesting that platelet activation in feeding coronary arteries of the collateral network has the potential to cause collateral vasoconstriction.
Methods. The subjects consisted of 22 patients with effort angina and reproducible ischemic threshold (group A, 11 patients with thrombolysis in myocardial infarction (TIMI) grade 2 or 3 flow of the ischemia-related coronary artery and Rentrop’s collateral index 0 or 1; group B, 11 patients with TIMI grade 0 or 1 flow and Rentrop’s collateral index 2 or 3). We repeated the symptom-limited treadmill exercise test using the Balke–Ware protocol and exercise tetrofosmin myocardial perfusion scintigraphy with and without pretreatment with 200 mg orally administered sarpogrelate. Each exercise test was performed at 9:00 a.m. on different days. The order of tests with and without sarpogrelate was randomized.
Results. In group A, sarpogrelate increased neither exercise time at 0.1 mV ST depression nor double product at 0.1 mV ST depression. In contrast, in group B sarpogrelate increased the exercise duration at 0.1 mV ST depression from 181 ± 112 (SD) to 248 ± 131 s (p < 0.05) and also increased the double product at 0.1 mV ST depression by 21% (p < 0.01). The severity score using myocardial perfusion scintigraphy at the same workload was significantly (p < 0.01) decreased by 37% in group B, but not in group A (11%), due to the sarpogrelate treatment.
Conclusions. Sarpogrelate augments flow reserve of the collateral circulation and improves exercise capacity in anginal patients with well-developed collaterals. These findings indicate that a serotonin blocker, sarpogrelate, is useful not only as an antiplatelet drugs, but as an antianginal drug.
This article has been cited by other articles:
|
|
|
|
 
M Fujita and K Tambara
Recent insights into human coronary collateral development
Heart,
March 1, 2004;
90(3):
246 - 250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hironaka, M. Hongo, A. Sakai, E. Mawatari, F. Terasawa, N. Okumura, A. Yamazaki, Y. Ushiyama, Y. Yazaki, and O. Kinoshita
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats
Cardiovasc Res,
December 1, 2003;
60(3):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Janiak, P. Lainee, Y. Grataloup, C.-E. Luyt, J.-P. Bidouard, J.-B. Michel, S. E O'Connor, and J.-M. Herbert
Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat
Cardiovasc Res,
November 1, 2002;
56(2):
293 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shimizu, S. Minatoguchi, K. Hashimoto, Y. Uno, M. Arai, N. Wang, X. Chen, C. Lu, G. Takemura, M. Shimomura, et al.
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts
J. Am. Coll. Cardiol.,
October 2, 2002;
40(7):
1347 - 1355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Brasil, R. M. Temsah, K. Kumar, H. Kumamoto, N. Takeda, and N. S. Dhalla
Blockade of 5-HT2A Receptors by Sarpogrelate Protects the Heart Against Myocardial Infarction in Rats
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2002;
7(1):
53 - 59.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Fujita
Heparin and angiogenic therapy
Eur. Heart J.,
February 2, 2000;
21(4):
270 - 274.
[PDF]
|
|
|
|
|
|
|
S. K. Sharma, P. Zahradka, D. Chapman, H. Kumamoto, N. Takeda, and N. S. Dhalla
Inhibition of Serotonin-Induced Vascular Smooth Muscle Cell Proliferation by Sarpogrelate
J. Pharmacol. Exp. Ther.,
September 1, 1999;
290(3):
1475 - 1481.
[Abstract]
[Full Text]
|
|
|
|
